Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 10/30/23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for PalazestrantGlobeNewsWire • 10/22/23
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of DirectorsGlobeNewsWire • 10/17/23
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO CongressGlobeNewsWire • 10/16/23
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor ActivityGlobeNewsWire • 10/12/23
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to TradeZacks Investment Research • 10/11/23
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep goingZacks Investment Research • 10/11/23
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?Zacks Investment Research • 09/25/23
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/20/23
Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should KnowZacks Investment Research • 09/08/23
What Makes Olema Pharmaceuticals, Inc. (OLMA) a Good Fit for 'Trend Investing'Zacks Investment Research • 09/08/23
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/23
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewsWire • 08/01/23
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 StudyGlobeNewsWire • 05/11/23